• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
The ESC Textbook of Heart Failure

The ESC Textbook of Heart Failure

9780198891628
1 228,50 zł
1 105,65 zł Zniżka 122,85 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 1 105,65 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
The ESC Textbook of Heart Failure is the latest addition to the European Society of Cardiology (ESC) publications portfolio and is fully supported by the European Heart Failure Association. The textbook brings together internationally renowned experts in the field of heart failure to present an up-to-date understanding of all aspects of this chronic condition that worsens with time. It is estimated that the worldwide population of patients suffering from heart failure is approximately 26 million. This clinically oriented work reflects contemporary European guidelines from the ESC and the European Heart Failure Association and summarizes the latest evidence from clinical trials. Made up of eighteen different sections the textbook covers the epidemiology, etiology, prevention, pathophysiology, and clinical phenotypes of heart failure. The assessment and management of chronic, acute, and advance heart failure are all discussed in detail. As well as chapters dedicated to self-care and patient education, the multidisciplinary approach to heart failure management, and clinical trial design and interpretation. The future direction of the field is discussed throughout withseparate chapters on digital health, big data, and telemedicine/remote monitoring in heart failure also included. A must read for cardiovascular healthcare specialists in Europe and across the world it should also appeal to those in training, general physicians and those caring of the elderly, cardiothoracic surgeons, primary care doctors, and specialist nurses too.
Szczegóły produktu
OUP Oxford
101900
9780198891628
9780198891628

Opis

Rok wydania
2023
Numer wydania
1
Oprawa
twarda
Liczba stron
1040
Wymiary (mm)
219 x 276
Waga (g)
2776
  • Section 1: Universal definition of heart failure; Universal definition of heart failure; Section 2: Epidemiology of heart failure; Epidemiology of heart failure; Section 3: Etiology of heart failure; Coronary artery disease; Hypertension; Valvular heart disease; Genetic basis of cardiomyopathies; Dilated and hypokinetic non-dilated cardiomyopathy; Hypertrophic cardiomyopathy; Restrictive cardiomyopathy; Arrhythmogenic right ventricular cardiomyopathy; Peripartum cardiomyopathy; Takotsubo cardiomyopathy; Myocarditis and pericarditis; Congenital heart disease; Endocrine and metabolic disorders; Obesity; Cancer and cancer therapy; Toxins (e.g. alcohol etc.) and infections; Section 4: Prevention of heart failure; Prevention of heart failure; Section 5: Pathophysiology of heart failure; Molecular and cellular mechanisms; Alterations in myocardial metabolism; Ventricular remodelling; Neurohormonal activation; Immune-mediated mechanisms; Inflammation, oxidative stress and endothelial dysfunction; Alterations in peripheral circulation and renal function; Systemic adaptations in metabolism and nutritive status; Section 6: Clinical phenotypes of chronic heart failure; HFrEF; HFmrEF; HFpEF; Right heart failure; Section 7: Chronic heart failure: diagnostic and prognostic assessment; Clinical assessment; Biomarkers in diagnostic and prognostic assessment; Echocardiography; Nuclear medicine; Cardiac computed tomography; Cardiac magnetic resonance; Cardiopulmonary exercise; Cardiac catheterization, invasive imaging and haemodynamic assessment; Section 8: Chronic heart failure: pharmacological management; Angiotensin converting enzyme inhibitors; Angiotensin I receptor blockers; ARNI; Beta-blockers; Mineralocorticoid receptor agonists; Ivabradine; Vasodilators; Digitalis glycosides; Diuretics; Inotropes and inodilators; SGLT2 inhibitors; Ancillary pharmacological treatment options; New and emerging therapies; Section 9: Chronic heart failure: non-pharmacological management; Implantable cardioverter defibrillator; Cardiac resynchronization therapy; Cardiac surgery; Valve interventions; Ancillary procedures; Cardiac rehabilitation; Section 10: Acute heart failure; Acute heart failure: diagnostic and prognostic assessment; Acute heart failure: management; Section 11: Advanced heart failure; Advanced heart failure: assessment; Advanced heart failure: management; Mechanical circulatory support; Heart transplantation; Palliative care and end-of-life management; Section 12: Comorbidities and clinical conditions; Chronic kidney disease: Clinical Aspects of Chronic Kidney Disease in Heart Failure; Dyskalaemia; Chronic lung disease; Ventilatory Abnormalities and Sleep Disordered Breathing; Pulmonary hypertension; Cardiac rhythm disorders; Management of atrial fibrillation in heart failure; Diabetes, metabolic syndrome and endocrine disorders; Systemic immune medicated diseases; Liver and gut dysfunction; Anaemia and iron deficiency; Depression and cognitive impairment; Cancer; Pregnancy; Frailty; Section 13: Self-care and patient education; Self-care and patient education; Section 14: Multidisciplinary approach to heart failure management; Multidisciplinary approach to heart failure management; Section 15: Clinical trial design and interpretation; Clinical trial design and interpretation; Section 16: Digital health in heart failure; Digital health in heart failure; Section 17: Big data in heart failure; Big data in heart failure; Section 18: Telemedicine and remote monitoring; Telemedicine and remote monitoring;
Zobacz także
Komentarze (0)